- SAB Biotherapeutics Provides SAB-142 Trial Update
- SAB Biotherapeutics to Present at INNODIA Annual Meeting
- SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
- SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
- SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
- SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- SAB Biotherapeutics Announces Executive Leadership Change
- SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
- SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
More ▼
Key statistics
On Friday, SAB Biotherapeutics Inc (SABS:NAQ) closed at 4.25, 6.25% above its 52-week low of 4.00, set on Mar 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.10 |
---|---|
High | 4.39 |
Low | 4.10 |
Bid | 3.85 |
Offer | 5.00 |
Previous close | 4.01 |
Average volume | 2.64k |
---|---|
Shares outstanding | 9.23m |
Free float | 7.46m |
P/E (TTM) | -- |
Market cap | 39.21m USD |
EPS (TTM) | -7.18 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 20:47 BST.
More ▼